{"organizations": [], "uuid": "ee745b9175543d7491e3bd4bde6f85cd93a8c679", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kadmon-posts-positive-topline-resu/brief-kadmon-posts-positive-topline-results-from-phase-2-study-of-kd025-in-idiopathic-pulmonary-fibrosis-idUSFWN1Q21DU", "country": "US", "domain_rank": 408, "title": "BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.987, "site_type": "news", "published": "2018-02-13T05:11:00.000+02:00", "replies_count": 0, "uuid": "ee745b9175543d7491e3bd4bde6f85cd93a8c679"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kadmon-posts-positive-topline-resu/brief-kadmon-posts-positive-topline-results-from-phase-2-study-of-kd025-in-idiopathic-pulmonary-fibrosis-idUSFWN1Q21DU", "ord_in_thread": 0, "title": "BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis", "locations": [], "entities": {"persons": [{"name": "kadmon", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "kadmon holdings inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Kadmon Holdings Inc:\n* KADMON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF KD025 IN IDIOPATHIC PULMONARY FIBROSIS\n* KADMON HOLDINGS INC - ‍KD025 WAS WELL TOLERATED AND DEMONSTRATED CLINICAL BENEFIT​\n* KADMON HOLDINGS INC - ‍KD025 HAD NO DRUG-RELATED SERIOUS ADVERSE EVENTS IN PHASE 2 STUDY​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T05:11:00.000+02:00", "crawled": "2018-02-13T16:01:43.000+02:00", "highlightTitle": ""}